HLA-B57
HLA-B serotype
HLA-B57 (B57) is an HLA-B serotype. B57 is a split antigen from the B17 broad antigen, the sister serotype being B58. The serotype identifies the more common HLA-B*57 gene products. (For terminology help see: HLA-serotype tutorial.) Like B58, B57 is involved in drug-induced inflammatory skin disorders.
Disease
HLA-B*5701 is associated with drug-induced inflammatory disease of the skin. Individuals with B57 are more sensitive to the drug abacavir. Abacavir is an antiretroviral drug used in treatment of HIV, however in sensitive individuals fever, skin rash, fatigue, gastrointestinal symptoms such as nausea, vomiting, diarrhea or abdominal pain and respiratory symptoms such as pharyngitis, dyspnea, or cough can develop. FDA has advised that people from at-risk ethnic groups, (see alle distribution table) be screened prior to drug-therapy.
[Note: phenotype frequencies are roughly double allele frequencies -tabled values- when allele frequency is less than 30%]
The mechanism by which abacavir causes this type 4 hypersensitivity reaction is by binding in the antigen-binding cleft of the HLA-B*57:01 protein, allowing new, "non-self" antigens to bind and be presented to T cells.
Begin with the source’s own compact description: “HLA-B57” is hLA-B serotype. The dossier treats that line as a proposition to test through HLA-B57, HLA-B and serotype, not as a finished interpretation.
Why this record matters
The phrase “hLA-B serotype” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated May 29, 2025. The linked authority identifier is Q5630113. None of the 0 selected statements returned an explicit reference.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “HLA-B57”, its source revision and the description used here.
- Expand the search: follow HLA-B57 primary sources, HLA-B57 archive and HLA-B57 research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “HLA-B57”?
- Which institution is responsible for the underlying evidence?
- Which cited source is closest to the event, object or claim?
Search terms from this dossier
This entry incorporates text from “HLA-B57” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.